{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125386","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.665342+00:00","generated_at":"2026-05-30T02:06:10.029295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track","bullets":["Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.","R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).","Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.","Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.","Appointed Keith Lui as SVP of Commercial and Medical Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125386","json":"https://secwatch.observer/filing/0000950170-24-125386.json","markdown":"https://secwatch.observer/filing/0000950170-24-125386.md","text":"https://secwatch.observer/filing/0000950170-24-125386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/0000950170-24-125386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/oric-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:06:10.029295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}